Genetic Screening and Targeted Treatment Halt Paget Disease Genetic Screening and Targeted Treatment Halt Paget Disease
A single infusion of zoledronic acid substantially reduced existing bone lesions and biochemical markers of bone turnover over 7 years.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 15, 2024 Category: Consumer Health News Tags: Rheumatology Source Type: news
Venus Remedies gets marketing authorisation from Philippines, Saudi Arabia for three oncology drugs
Pharma major Venus Remedies on Wednesday said it has received marketing authorisation from Philippines and Saudi Arabia for three oncology drugs. In a statement, the Panchkula-based company said it has received regulatory approval from Philippines, the second largest market in the Association of Southeast Asian Nations (ASEAN) region, for chemotherapy drug paclitaxel and zoledronic acid. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 6, 2023 Category: Pharmaceuticals Source Type: news
Fracture Reduction Greater with Denosumab vs Zoledronic Acid Fracture Reduction Greater with Denosumab vs Zoledronic Acid
In the absence of a randomized comparison trial on fracture risk reduction, researchers use negative control outcome to compare the two drugs.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 16, 2023 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
Long-term Side Effects After Zoledronic Acid Infusion Long-term Side Effects After Zoledronic Acid Infusion
This case highlights the potential of severe, life-threatening side-effects following a single intravenous zoledronic acid infusion.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 17, 2023 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Netherlands Cancer Institute Tests New Mesothelioma Therapy
Research for a new type of mesothelioma treatment is underway at the Netherlands Cancer Institute. Scientists are exploring a novel combination of existing medications for patients with BAP1 genetic mutations.
More than half of all mesothelioma patients show alterations in the BAP1 tumor-suppressor gene. An altered BAP1 gene allows for vulnerabilities that make specific treatments more effective. The combination treatment led to about a four-week increase in median survival.
Researchers have previously only explored the combination of zoledronic acid and tazemetostat in single cells and animal models. This late...
Source: Asbestos and Mesothelioma News - February 15, 2023 Category: Environmental Health Authors: Amy Edel Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Cardiovascular Risks Not Increased With Denosumab
(MedPage Today) -- AUSTIN, Texas – Denosumab (Prolia, Xgeva) carried no increased risk of cardiovascular disease or stroke when compared with zoledronic acid (Reclast, Zometa) to combat osteoporosis, researchers found.
Compared with zoledronic... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 13, 2022 Category: Cardiology Source Type: news
Jaw Osteonecrosis Tied to Treatment for Bone Metastases
Cancer type, oral health, and frequency of dosing for zoledronic acid linked to risk for osteonecrosis of the jaw (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 4, 2021 Category: Cancer & Oncology Tags: Oncology, Orthopedics, Pharmacy, Journal, Source Type: news
Jaw Osteonecrosis Tied to Treatment for Bone Metastases
MONDAY, Jan. 4, 2021 -- The cumulative three-year incidence of osteonecrosis of the jaw (ONJ) is 2.8 percent in cancer patients receiving zoledronic acid for metastatic bone disease (MBD), according to a study published online Dec. 17 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2021 Category: Pharmaceuticals Source Type: news
Jaw Necrosis Risk in Cancer Patients on Zoledronic Acid Varies With Dosing Jaw Necrosis Risk in Cancer Patients on Zoledronic Acid Varies With Dosing
In patients treated with zoledronic acid for bone metastases, the risk of osteonecrosis of the jaw was associated with cancer type, oral health and dosing frequency, researchers found in a recent study.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - December 28, 2020 Category: Orthopaedics Tags: Dental & Oral Health News Source Type: news
Use of a homozygous G608G progeria mouse model for degenerative joint diseases research
(Beth Israel Deaconess Medical Center) In a study published today in the journal Proceedings of the National Academies of Science, researchers led by Ara Nazarian, PhD, a principal investigator in the Center for Advanced Orthopaedic Studies at BIDMC, investigated the musculoskeletal phenotype of the homozygous G608G BAC-transgenic progeria mouse model, developed at Dr. Collins' lab at the National Institutes of Health, and determined the phenotypic changes of these mice after a five-arm preclinical trial of different treatment combinations with lonafarnib, pravastatin, and zoledronic acid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 11, 2020 Category: International Medicine & Public Health Source Type: news
UK Oncologist Proposes Novel Treatment for Mesothelioma
Medical oncologist Dr. Angus Dalgleish never did like standard of care treatment for pleural mesothelioma cancer, even when he reluctantly recommended it in the past.
He believes now there is something better.
Dalgleish, of St. George’s Hospital, University of London, recently published a case report detailing a novel treatment regimen that turned a six-month life expectancy for one patient into a six-year survival.
The treatment involved a series of anti-inflammatories that included low-dose naltrexone, vitamin D3 supplements and the vaccine IMM-101, which heightens a patient’s own immune response.
“Initially, I was...
Source: Asbestos and Mesothelioma News - April 22, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news
Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer Zoledronic Acid and Neoadjuvant Chemo in HER2- Breast Cancer
While adjuvant bisphosphonates are associated with longer survival in postmenopausal women with breast cancer, the same cannot be said for neoadjuvant bisphosphonates.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Denosumab Increasingly Used in Myeloma Despite High Cost Denosumab Increasingly Used in Myeloma Despite High Cost
Denosumab has captured 40% of the market share in just over a year despite a lack of superiority with zoledronic acid and a much higher price tag.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 18, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Zoledronic Acid Reduces Periodontal Disease in Osteoporosis Patients Zoledronic Acid Reduces Periodontal Disease in Osteoporosis Patients
Once-yearly zoledronic acid helps prevent symptomatic periodontal disease in osteoporosis patients, according to industry-funded research.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Cancer Bone Mets Therapy: One in 40 Patients at Risk for ONJ Cancer Bone Mets Therapy: One in 40 Patients at Risk for ONJ
Clinicians should be aware of near-fivefold raised risk for osteonecrosis of the jaw (ONJ) if zoledronic acid is used to prevent cancer bone metastases, warn researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 5, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
